Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149004 | 0.86 | PPARG (0.73) | PPARG | |
| SCHEMBL5217146 | 0.85 | PPARG (0.72) | PPARG | |
| Acetic Acid SCHEMBL322553 | 0.85 | PPARG (0.72) | PPARG | |
| SCHEMBL18979323 | 0.85 | PPARG (1.00) | PPARG | |
| SCHEMBL14381244 | 0.85 | PPARG (0.86) | PPARG | |
| SCHEMBL14493047 | 0.85 | PPARG (0.74) | PPARG | |
| SCHEMBL14381315 | 0.85 | PPARG (1.00) | PPARG | |
| SCHEMBL14381420 | 0.83 | PPARG (0.72) | PPARG | |
| SCHEMBL14493040 | 0.83 | PPARG (0.83) | PPARG | |
| SCHEMBL14493053 | 0.83 | PPARG (0.69) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459228-B1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2020-03-04 | — | — | EP | claimed |
| EP-2459171-B1 | Long acting insulin composition | SANOFI AVENTIS DEUTSCHLAND (DE) | 2017-06-21 | — | — | EP | claimed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | claimed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | claimed |
| EP-2459228-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | Sanofi-Aventis Deutschland GmbH (DE) | 2012-06-06 | — | — | EP | claimed |
| EP-2459171-A1 | LONG ACTING INSULIN COMPOSITION | Sanofi-Aventis Deutschland GmbH (DE) | 2012-06-06 | — | — | EP | claimed |
| WO-2011012719-A1 | LONG ACTING INSULIN COMPOSITION | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |
| WO-2011012718-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |
| US-11576894-B2 | Combination therapy for the treatment of diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-14 | — | — | US | disclosed |
| EP-2459228-B1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-2451482-B1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-01 | — | — | EP | disclosed |
| EP-2459171-B1 | Long acting insulin composition | SANOFI AVENTIS DEUTSCHLAND (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20170128414-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-11 | — | — | US | disclosed |
| EP-2590631-B1 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-26 | — | — | EP | disclosed |
| EP-1333887-B1 | COMBINATION THERAPY COMPRISING ANTI-DIABETIC AND ANTICONVULSANT AGENTS | ORTHO MCNEIL PHARM INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20040157785-A1 | Combination therapy comprising anti-diabetic and anticonvulsant agents | CONNOR GREGORY S (US) | 2004-08-12 | — | — | US | disclosed |
| US-6686337-B2 | SYNERGISTIC MIXTURE | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1333887-A2 | COMBINATION THERAPY COMPRISING ANTI-DIABETIC AND ANTICONVULSANT AGENTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020147157-A1 | Combination therapy comprising anti-diabetic and anticonvulsant agents | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002064210-A2 | COMBINATION THERAPY COMPRISING ANTI-DIABETIC AND ANTICONVULSANT AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | PPARG 1554/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | PPARG 1890/4885 |
| US-20020147157-A1 | Combination therapy comprising anti-diabetic and anticonvulsant agents | GABRE, IAPP, GABBR2 | PPARG 1281/4885 |
| US-20170128414-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, SLC2A2 | PPARG 245/4885 |
| US-11576894-B2 | Combination therapy for the treatment of diabetes | SLC5A2, SLC5A1, SLC2A2 | PPARG 245/4885 |
| US-20040157785-A1 | Combination therapy comprising anti-diabetic and anticonvulsant agents | GABRE, IAPP, GABBR2 | PPARG 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.